Department of Obstetrics and Gynecology, Beijing Luhe Hospital, Capital Medical University, Beijing.
Department of English, Beijing University of technology, Beijing, China.
J Clin Ultrasound. 2023 Jun;51(5):879-886. doi: 10.1002/jcu.23438. Epub 2023 Mar 16.
To compare the efficacy and safety of percutaneous microwave ablation (PMWA) and transcervical resection of myoma (TCRM) for submucosal fibroids.
From January 2019 to January 2021, we conducted a randomized controlled study involving patients with symptomatic uterine submucosal fibroids. Questionnaires were also used to measure the uterine fibroid symptom (UFS) scores and quality of life (QoL) scores before and after treatment at 3, 6, and 12 months. Outcomes, adverse events, hemoglobin recovery, and submucosal fibroid volume of both groups were also compared. Operation time, amount of bleeding, hospital stay time, and occurrence of complications were compared in groups with fibroids of different lengths.
Follow-up after surgery showed that UFS scores at 3, 6, and 12 months were significantly lower in each group, while QoL scores increased significantly. For fibroids less than 3 cm, surgical time was 34.2 ± 9.9 min, incidence of perioperative complications was 4.2%, and both decreased significantly, compared to the surgical time of the PMWA group (40.0 ± 8.1 min) and incidence of perioperative complications (24%; p < .05 for both). For uterine submucosal fibroids >5 cm, the operation time in the PMWA group was 92.7 ± 16.0 min, intraoperative bleeding volume was 22.7 ± 6.4 mL, and hospital stay was 2.7 ± 1.1 days, which were significantly less than the procedural time (107 ± 11.9 min), intraoperative bleeding loss (45.9 ± 12.8 mL), and length of hospital stay (5.0 ± 1.1 days) in the TCRM group. The differences were statistically significant (p < .05).
PMWA and TCRM were both effective treatments for uterine submucosal fibroids. For fibroids shorter than 3 cm in length, especially pedicled submucosal fibroids, TCRM has absolute advantages; however, for uterine submucosal fibroids >5 cm, PMWA avoids perioperative complications, such as uterine perforation, water poisoning syndrome, and the need for repeat surgery, and is considered the preferred mode of treatment. Therefore, personalized treatment should be used for different patients with uterine submucosal fibroids.
比较经阴道子宫肌瘤切除术(TCRM)与经皮微波消融术(PMWA)治疗黏膜下子宫肌瘤的疗效和安全性。
本研究为 2019 年 1 月至 2021 年 1 月期间进行的一项随机对照研究,纳入了有症状的黏膜下子宫肌瘤患者。使用问卷调查评估治疗前和治疗后 3、6、12 个月的子宫肌瘤症状(UFS)评分和生活质量(QoL)评分。比较两组患者的不良事件、血红蛋白恢复情况和黏膜下肌瘤体积,比较不同长度肌瘤患者的手术时间、出血量、住院时间和并发症发生情况。
术后随访显示,各组患者 UFS 评分在 3、6、12 个月时均明显降低,QoL 评分明显升高。对于小于 3cm 的肌瘤,TCRM 组的手术时间为 34.2±9.9min,围手术期并发症发生率为 4.2%,均明显低于 PMWA 组(手术时间 40.0±8.1min,围手术期并发症发生率 24%)(均 P<.05)。对于大于 5cm 的黏膜下肌瘤,PMWA 组的手术时间为 92.7±16.0min,术中出血量为 22.7±6.4mL,住院时间为 2.7±1.1d,均明显少于 TCRM 组(手术时间 107±11.9min,术中出血量 45.9±12.8mL,住院时间 5.0±1.1d)(均 P<.05)。
PMWA 和 TCRM 均是治疗黏膜下子宫肌瘤的有效方法。对于长度小于 3cm 的肌瘤,特别是有蒂黏膜下肌瘤,TCRM 具有绝对优势;然而,对于大于 5cm 的黏膜下肌瘤,PMWA 可避免子宫穿孔、水中毒综合征和需要再次手术等围手术期并发症,被认为是首选的治疗方式。因此,对于不同的黏膜下子宫肌瘤患者应采用个体化治疗。